Recombinant Adenovirus Vector Production Using VPC2.0 Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for producing large-scale quantities of high-quality recombinant adenovirus vectors, particularly Nadofaragene firadenovec, needed for clinical applications such as treating bladder cancer.
Innovation Solution
A method involving infecting Viral Production Cells 2.0 (VPC2.0) with a non-replicating recombinant adenovirus vector containing a transgene encoding human interferon, such as interferon alpha-2b, and harvesting the vector after 24-48 hours, which includes lysing and centrifuging the cells, results in increased production up to 500% more than traditional methods using HEK293 cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods using HEK293 cells are used to produce recombinant adenovirus vectors, then the production process is simple and well-established, but the production quantity is insufficient to meet clinical demand
Solution Approach 1:
The patent changes the cell line parameter from HEK293 to VPC2.0 cells, which are specifically engineered for high-level adenovirus production. This parameter change enables significantly increased production quantities (up to 500% greater) while maintaining a relatively straightforward production process, resolving the contradiction between productivity and process complexity.
2Productivity
If higher production quantities are achieved using VPC2.0 cells, then clinical demand is met, but the method requires specific cell line characteristics and optimized conditions
Solution Approach 1:
The patent employs VPC2.0 cells, which are a specialized cell line that can be readily obtained and used for production. These cells are designed for high productivity and can be scaled according to demand, providing ease of manufacture while achieving high production quantities. The cell line serves as a disposable working medium that can be optimized for each production run.
Solution Approach 2:
By optimizing parameters such as multiplicity of infection (MOI) to 100-300, infection cell density to 2-4×10^6 viable cells/mL, and harvest time to 24-48 hours, the patent achieves high production quantities while maintaining manufacturing ease. These parameter optimizations allow the process to be straightforward and scalable.
3Productivity
If the vector is harvested at later time points (24-48 hours), then production quantity increases, but the production time is extended
Solution Approach 1:
The patent optimizes the harvest time parameter to 24-48 hours post-infection, which balances production quantity and production time. This parameter optimization ensures that sufficient viral particles are produced while avoiding excessive time extension. The specific timing allows for maximum viral yield without unnecessary delays in the production process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances the production of Nadofaragene firadenovec, meeting clinical demands by producing quantities up to 500% greater than previous methods, facilitating effective treatment of bladder cancer.
Implementation Method 1
infecting Viral Production Cells 2.0 (VPC2.0 cells) with at least one non-replicating recombinant adenovirus vector containing a transgene encoding human interferon
Implementation Method 2
the method further comprises lysing the VPC2.0 cells with a lysing agent prior to harvesting
Implementation Method 3
the method further comprises centrifuging the lysed cells
Data Source
AI summary
Disclosed herein are methods for producing recombinant adenoviruses or recombinant adenovirus vectors.